{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:45:33Z","timestamp":1793677533285,"version":"4.5.1"},"reference-count":121,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:sec id=\"ab-jrv260014-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Alcohol-related liver disease (ALD) is the leading cause of liver-related morbidity and mortality, and the most common indication for liver transplant in Europe and the US. In the US, ALD-related mortality increased from 6.7 deaths per 100\u202f000 people in 1999 to 12.5 deaths per 100\u202f000 people in 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260014-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>ALD can develop with long-term daily alcohol consumption of more than 20 g per day for women (1.4 standard drinks\/d) and more than 30 g per day for men (2.1 standard drinks\/d), with 1 standard drink containing 14 g of ethanol, equivalent to approximately 12 oz of beer, 5 oz of wine, or 1.5 oz of distilled spirits. ALD encompasses reversible steatosis; steatohepatitis, which can cause alcohol-associated hepatitis; and fibrosis, which can cause cirrhosis, portal hypertension, hepatic decompensation, and hepatocellular carcinoma. Risk factors for ALD progression include increased quantity and duration of alcohol use, female sex, older age, obesity, type 2 diabetes, metabolic syndrome, smoking, viral hepatitis, and specific genetic variants. Most patients with ALD (90%) are asymptomatic or have nonspecific symptoms, such as fatigue. Alcohol-associated hepatitis often causes fever, anorexia, nausea, vomiting, abdominal pain, and jaundice. Individuals with decompensated cirrhosis typically have ascites, variceal bleeding, jaundice, and\/or hepatic encephalopathy. Noninvasive liver fibrosis tests, such as the Fibrosis-4 score (which includes alanine transaminase, aspartate aminotransferase, platelet count, and age), and more specific second-line tests, including liver stiffness measurement (vibration-controlled transient elastography) and blood-based fibrosis markers such as the enhanced liver fibrosis test and N-terminal propeptide of type III collagen, provide early diagnosis of ALD and assess liver fibrosis severity, which is the strongest predictor of liver-related outcomes. Alcohol cessation interventions such as motivational enhancement therapy, cognitive behavioral therapy, and pharmacologic therapy (eg, baclofen, naltrexone) are recommended to prevent disease progression. Because alcohol consumption is often underreported, screening tools, such as the Alcohol Use Disorders Identification Test, and sensitive biomarkers of recent alcohol intake (eg, blood phosphatidylethanol) may improve clinical accuracy. Sustained abstinence from alcohol is the primary treatment for ALD. Among patients with alcohol-related cirrhosis, alcohol abstinence over a median follow-up of 36 months was associated with reduced risk of liver-related mortality (adjusted hazard ratio, 0.43 [95% CI, 0.26-0.70]) and all-cause mortality (adjusted hazard ratio, 0.45 [95% CI, 0.30-0.67]). Liver transplant evaluation should be considered for patients with severe alcohol-associated hepatitis or decompensated cirrhosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260014-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>People with chronic daily heavy alcohol consumption should be assessed for ALD with noninvasive testing. The primary treatment goal is alcohol cessation. Patients with severe alcohol-associated hepatitis or decompensated cirrhosis should be considered for liver transplant.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2026.12038","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:30:11Z","timestamp":1783355411000},"page":"413","source":"Crossref","is-referenced-by-count":6,"title":["Alcohol-Related Liver Disease"],"prefix":"10.1001","volume":"336","author":[{"given":"Aleksander","family":"Krag","sequence":"first","affiliation":[{"name":"Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark"},{"name":"Institute of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"\u00c5berg","sequence":"additional","affiliation":[{"name":"Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mellinger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology & Hepatology, Henry Ford Health-Michigan State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Liver Diseases, University of Southern California Keck School of Medicine, Los Angeles"},{"name":"Institute for Addiction Science, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Israelsen","sequence":"additional","affiliation":[{"name":"Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark"},{"name":"Institute of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"jrv260014r1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"9","key":"jrv260014r2","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/S2468-2667(25)00174-4","article-title":"National, regional, and global statistics on alcohol consumption and associated burden of disease 2000-20: a modelling study and comparative risk assessment.","volume":"10","author":"Shield","year":"2025","journal-title":"Lancet Public Health"},{"issue":"6","key":"jrv260014r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.14857","article-title":"Alcohol-associated liver disease mortality.","volume":"8","author":"Pan","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"17","key":"jrv260014r4","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1001\/jama.2022.4308","article-title":"Alcohol-related deaths during the COVID-19 pandemic.","volume":"327","author":"White","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"jrv260014r5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.7326\/M20-7271","article-title":"Retail alcohol and tobacco sales during COVID-19.","volume":"174","author":"Lee","year":"2021","journal-title":"Ann Intern Med"},{"issue":"1","key":"jrv260014r6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.7326\/ANNALS-24-02157","article-title":"Trends in alcohol use after the COVID-19 pandemic: a national cross-sectional study.","volume":"178","author":"Ayyala-Somayajula","year":"2025","journal-title":"Ann Intern Med"},{"issue":"2","key":"jrv260014r7","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/HEP.0000000000000914","article-title":"Waitlisting and liver transplantation for MetALD in the United States: an analysis of the UNOS national registry.","volume":"81","author":"Ochoa-Allemant","year":"2025","journal-title":"Hepatology"},{"issue":"10319","key":"jrv260014r8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"jrv260014r9","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.cgh.2019.01.026","article-title":"Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide.","volume":"17","author":"Shah","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"jrv260014r10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"jrv260014r11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/S2468-1253(23)00192-9","article-title":"Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study.","volume":"8","author":"Kann","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"jrv260014r12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease.","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"jrv260014r13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"issue":"12","key":"jrv260014r14","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/j.cgh.2025.01.003","article-title":"Association of alcohol and incremental cardiometabolic risk factors with liver disease: a national cross-sectional study.","volume":"23","author":"Lee","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"jrv260014r15","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jamainternmed.2025.1809","article-title":"Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease.","volume":"185","author":"Ochoa-Allemant","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"6","key":"jrv260014r16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"issue":"7","key":"jrv260014r17","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/dar.13286","article-title":"The role of alcohol use in the aetiology and progression of liver disease: a narrative review and a quantification.","volume":"40","author":"Rehm","year":"2021","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"jrv260014r18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/HEP.0000000000000381","article-title":"Emerging targets for therapy in ALD: lessons from NASH.","volume":"80","author":"Singal","year":"2024","journal-title":"Hepatology"},{"issue":"5","key":"jrv260014r19","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1053\/j.gastro.2011.09.002","article-title":"Alcoholic liver disease: pathogenesis and new therapeutic targets.","volume":"141","author":"Gao","year":"2011","journal-title":"Gastroenterology"},{"issue":"5","key":"jrv260014r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100325","article-title":"Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication.","volume":"3","author":"Israelsen","year":"2021","journal-title":"JHEP Rep"},{"issue":"2","key":"jrv260014r21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2018.10.037","article-title":"Effect of ethanol on lipid metabolism.","volume":"70","author":"You","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"jrv260014r22","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/hep.29631","article-title":"Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population.","volume":"67","author":"\u00c5berg","year":"2018","journal-title":"Hepatology"},{"key":"jrv260014r23","doi-asserted-by":"publisher","first-page":"c1240","DOI":"10.1136\/bmj.c1240","article-title":"Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies.","volume":"340","author":"Hart","year":"2010","journal-title":"BMJ"},{"issue":"12","key":"jrv260014r24","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41575-023-00822-y","article-title":"The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.","volume":"20","author":"D\u00edaz","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"jrv260014r25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41588-024-01720-y","article-title":"Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis.","volume":"56","author":"Ghouse","year":"2024","journal-title":"Nat Genet"},{"issue":"3","key":"jrv260014r26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1055\/a-2630-0952","article-title":"MetALD: genetic factors and clinical outcomes.","volume":"45","author":"Israelsen","year":"2025","journal-title":"Semin Liver Dis"},{"issue":"1","key":"jrv260014r27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jhep.2025.02.039","article-title":"Hot and cold fibrosis: the role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis.","volume":"83","author":"de Zawadzki","year":"2025","journal-title":"J Hepatol"},{"issue":"10308","key":"jrv260014r28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis.","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"jrv260014r29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jhep.2024.12.030","article-title":"Differences between hepatocellular carcinoma caused by alcohol and other aetiologies.","volume":"82","author":"Ganne-Carri\u00e9","year":"2025","journal-title":"J Hepatol"},{"issue":"6","key":"jrv260014r30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S2468-1253(25)00376-0","article-title":"Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis.","volume":"11","author":"Younossi","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"jrv260014r31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41575-024-01022-y","article-title":"The steatotic liver disease burden paradox: unravelling the key role of alcohol.","volume":"22","author":"Torp","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"jrv260014r32","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jhep.2025.07.019","article-title":"Phosphatidylethanol in steatotic liver disease.","volume":"83","author":"Torp","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"jrv260014r33","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2468-1253(24)00427-8","article-title":"Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD.","volume":"10","author":"Krag","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"jrv260014r34","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000133","article-title":"Prevalence of alcohol-associated liver disease: a systematic review and meta-analysis.","volume":"7","author":"Amonker","year":"2023","journal-title":"Hepatol Commun"},{"issue":"2","key":"jrv260014r35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41395-018-0282-6","article-title":"Opportunities to prevent alcoholic liver cirrhosis in high-risk populations: a systematic review with meta-analysis.","volume":"114","author":"Askgaard","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"jrv260014r36","doi-asserted-by":"publisher","first-page":"879","DOI":"10.7326\/M23-0518","article-title":"National trends in alcohol use, metabolic syndrome, and liver disease from 1999 to 2018.","volume":"176","author":"Lee","year":"2023","journal-title":"Ann Intern Med"},{"issue":"10","key":"jrv260014r37","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","article-title":"Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis.","volume":"114","author":"Roerecke","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"jrv260014r38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.14309\/ajg.0000000000000833","article-title":"Obesity, diabetes, coffee, tea, and cannabis use alter risk for alcohol-related cirrhosis in 2 large cohorts of high-risk drinkers.","volume":"116","author":"Whitfield","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"jrv260014r39","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jhep.2014.12.005","article-title":"Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study.","volume":"62","author":"Askgaard","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"jrv260014r40","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/S2468-2667(18)30230-5","article-title":"Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK Million Women Study.","volume":"4","author":"Simpson","year":"2019","journal-title":"Lancet Public Health"},{"issue":"9","key":"jrv260014r41","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/liv.13408","article-title":"Binge drinking and the risk of liver events: A population-based cohort study.","volume":"37","author":"\u00c5berg","year":"2017","journal-title":"Liver Int"},{"issue":"1","key":"jrv260014r42","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-related liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases.","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"issue":"7540","key":"jrv260014r43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/bmj.38694.568981.80","article-title":"Food buying habits of people who buy wine or beer: cross sectional study.","volume":"332","author":"Johansen","year":"2006","journal-title":"BMJ"},{"key":"jrv260014r44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.11.038","article-title":"Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis.","author":"Israelsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"jrv260014r45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2021.10.005","article-title":"A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.","volume":"76","author":"Whitfield","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"jrv260014r46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1055\/a-2000-6680","article-title":"The changing epidemiology of alcohol-associated liver disease: gender, race, and risk factors.","volume":"43","author":"Anouti","year":"2023","journal-title":"Semin Liver Dis"},{"issue":"1","key":"jrv260014r47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2022.01.016","article-title":"Cigarette smoking and liver diseases.","volume":"77","author":"Marti-Aguado","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"jrv260014r48","doi-asserted-by":"publisher","first-page":"6880","DOI":"10.1038\/s41467-024-51314-9","article-title":"Diet modifies the association between alcohol consumption and severe alcohol-related liver disease incidence.","volume":"15","author":"Petermann-Rocha","year":"2024","journal-title":"Nat Commun"},{"key":"jrv260014r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.06.033","article-title":"Healthy eating and physical activity significantly lower sex-specific alcohol-attributable liver mortality in the United States.","author":"Vilar-Gomez","year":"2026","journal-title":"J Hepatol"},{"issue":"5","key":"jrv260014r50","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/apt.13523","article-title":"Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis.","volume":"43","author":"Kennedy","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"jrv260014r51","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL Clinical Practice Guidelines on nutrition in chronic liver disease.","volume":"70","author":"European Association for the Study of the Liver","year":"2019","journal-title":"J Hepatol"},{"issue":"8","key":"jrv260014r52","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/jama.2012.186","article-title":"Does this patient with liver disease have cirrhosis?","volume":"307","author":"Udell","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"jrv260014r53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice Guidelines: management of alcohol-related liver disease.","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"jrv260014r54","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S2468-1253(23)00010-9","article-title":"Rifaximin-a for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"8","author":"Israelsen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"jrv260014r55","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.dld.2024.01.195","article-title":"You can\u2019t handle the truth! comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patients.","volume":"56","author":"Scholten","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"5","key":"jrv260014r56","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cgh.2024.01.006","article-title":"Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis.","volume":"22","author":"Nasr","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"jrv260014r57","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.cgh.2025.02.007","article-title":"Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments.","volume":"23","author":"Israelsen","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"14","key":"jrv260014r58","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jama.2024.3101","article-title":"Does this patient have alcohol use disorder? the rational clinical examination systematic review.","volume":"331","author":"Wood","year":"2024","journal-title":"JAMA"},{"issue":"23","key":"jrv260014r59","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1001\/jama.2024.3607","article-title":"Blood testing for phosphatidylethanol.","volume":"331","author":"Mazhar","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"jrv260014r60","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2468-1253(25)00187-6","article-title":"Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study.","volume":"10","author":"Torp","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"jrv260014r61","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/LVT.0000000000000223","article-title":"\u201cBut I didn\u2019t drink!\u201d: what to do with discordant phosphatidylethanol results.","volume":"30","author":"Winder","year":"2024","journal-title":"Liver Transpl"},{"issue":"1","key":"jrv260014r62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG clinical guideline: alcohol-associated liver disease.","volume":"119","author":"Jophlin","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"jrv260014r63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101200","article-title":"Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake.","volume":"7","author":"Hansen","year":"2024","journal-title":"JHEP Rep"},{"issue":"5","key":"jrv260014r64","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jhep.2025.04.019","article-title":"Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes.","volume":"83","author":"Vaz","year":"2025","journal-title":"J Hepatol"},{"key":"jrv260014r65","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.10.005","article-title":"Prognostic performance of phosphatidylethanol with noninvasive liver fibrosis tests in alcohol-related liver disease.","author":"Torp","year":"2025","journal-title":"Gastroenterology"},{"issue":"5","key":"jrv260014r66","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jhep.2021.05.037","article-title":"Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.","volume":"75","author":"Rasmussen","year":"2021","journal-title":"J Hepatol"},{"issue":"7","key":"jrv260014r67","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/liv.15595","article-title":"Validation of scores of PRO-C3 to predict liver-related events in alcohol-related liver disease.","volume":"43","author":"Johansen","year":"2023","journal-title":"Liver Int"},{"issue":"3","key":"jrv260014r68","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jhep.2022.11.013","article-title":"Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort.","volume":"78","author":"Louvet","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"jrv260014r69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and treatment of alcohol-associated liver disease: a review.","volume":"326","author":"Singal","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"jrv260014r70","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S2468-1253(25)00097-4","article-title":"Screening for advanced steatotic liver disease.","volume":"10","author":"Johansen","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"17","key":"jrv260014r71","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis.","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv260014r72","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population.","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"jrv260014r73","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083182","article-title":"Use of new CORE risk score to predict 10 year risk of liver cirrhosis in general population: population based cohort study.","volume":"390","author":"Strandberg","year":"2025","journal-title":"BMJ"},{"issue":"10406","key":"jrv260014r74","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"jrv260014r75","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jhep.2022.02.021","article-title":"Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score.","volume":"77","author":"\u00c5berg","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"jrv260014r76","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis: 2021 update.","volume":"75","author":"European Association for the Study of the Liver","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"jrv260014r77","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/HEP.0000000000000845","article-title":"AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"jrv260014r78","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"issue":"10537","key":"jrv260014r79","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/S0140-6736(26)00354-5","article-title":"Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.","volume":"407","author":"Graupera","year":"2026","journal-title":"Lancet"},{"key":"jrv260014r80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.12.018","article-title":"Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals.","volume":"22","author":"Kjaergaard","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"jrv260014r81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101165","article-title":"Liver fibrosis screening increases alcohol abstinence.","volume":"6","author":"Avitabile","year":"2024","journal-title":"JHEP Rep"},{"key":"jrv260014r82","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102069","article-title":"Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD): an open-label pragmatic feasibility randomised controlled trial.","volume":"61","author":"Subhani","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"18","key":"jrv260014r83","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2023.5997","article-title":"Diagnosis and management of cirrhosis and its complications: a review.","volume":"329","author":"Tapper","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"jrv260014r84","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/alcalc\/agad051","article-title":"Efficacy of psychosocial interventions to reduce alcohol use in comorbid alcohol use disorder and alcohol-related liver disease: a systematic review of randomized controlled trials.","volume":"58","author":"Hemrage","year":"2023","journal-title":"Alcohol Alcohol"},{"issue":"11","key":"jrv260014r85","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1111\/add.12679","article-title":"Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial.","volume":"109","author":"Dieperink","year":"2014","journal-title":"Addiction"},{"issue":"16","key":"jrv260014r86","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1001\/archinte.159.16.1946","article-title":"A randomized trial of integrated outpatient treatment for medically ill alcoholic men.","volume":"159","author":"Willenbring","year":"1999","journal-title":"Arch Intern Med"},{"issue":"4","key":"jrv260014r87","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/acer.70018","article-title":"Contingency management to promote treatment engagement in comorbid alcohol use disorder and alcohol-related liver disease: findings from a pilot randomized controlled trial.","volume":"49","author":"Hemrage","year":"2025","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"issue":"5","key":"jrv260014r88","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000686","article-title":"Treatment of alcohol use disorder in alcohol-associated liver disease: a meta-analysis.","volume":"9","author":"Singal","year":"2025","journal-title":"Hepatol Commun"},{"issue":"9603","key":"jrv260014r89","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"jrv260014r90","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial.","volume":"212","author":"Morley","year":"2018","journal-title":"Br J Psychiatry"},{"issue":"3","key":"jrv260014r91","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40263-025-01254-9","article-title":"Clinical presentations and treatment of baclofen toxicity and withdrawal: a systematic review.","volume":"40","author":"Iqbal","year":"2026","journal-title":"CNS Drugs"},{"issue":"5","key":"jrv260014r92","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder.","volume":"5","author":"Vannier","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10540","key":"jrv260014r93","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"issue":"2S1","key":"jrv260014r94","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1016\/j.ajt.2025.01.022","article-title":"OPTN\/SRTR 2023 annual data report: liver.","volume":"25","author":"Kwong","year":"2025","journal-title":"Am J Transplant"},{"issue":"3","key":"jrv260014r95","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1001\/jamainternmed.2018.6536","article-title":"National trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States.","volume":"179","author":"Lee","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"16","key":"jrv260014r96","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"jrv260014r97","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S2468-1253(24)00232-2","article-title":"Global differences in the management of alcohol-associated hepatitis.","volume":"9","author":"Blaney","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"jrv260014r98","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.gastro.2018.04.009","article-title":"Outcomes of early liver transplantation for patients with severe alcoholic hepatitis.","volume":"155","author":"Lee","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"jrv260014r99","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/add.12139","article-title":"The relationship between minimum alcohol prices, outlet densities and alcohol-attributable deaths in British Columbia, 2002-09.","volume":"108","author":"Zhao","year":"2013","journal-title":"Addiction"},{"issue":"5","key":"jrv260014r100","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S2468-1253(21)00430-1","article-title":"Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study.","volume":"7","author":"Louvet","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"jrv260014r101","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001628","article-title":"Differential associations of cardiometabolic risk factors with liver-related events by alcohol consumption category: results from a large population-based study.","author":"Xue","year":"2025","journal-title":"Hepatology"},{"issue":"21","key":"jrv260014r102","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis.","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv260014r103","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"issue":"5","key":"jrv260014r104","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"18","key":"jrv260014r105","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv260014r106","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"jrv260014r107","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cgh.2023.07.009","article-title":"Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis.","volume":"22","author":"Elhence","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"jrv260014r108","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"jrv260014r109","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis.","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"jrv260014r110","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease.","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"9","key":"jrv260014r111","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","article-title":"Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis.","volume":"21","author":"Hofer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"jrv260014r112","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","article-title":"Accuracy of the enhanced liver fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease.","volume":"154","author":"Thiele","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"jrv260014r113","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1465-3362.2009.00153.x","article-title":"Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis.","volume":"29","author":"Rehm","year":"2010","journal-title":"Drug Alcohol Rev"},{"issue":"3","key":"jrv260014r115","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"issue":"10","key":"jrv260014r116","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000279","article-title":"Time trends in mortality and life expectancy in 22,658 patients hospitalized with alcohol-associated cirrhosis: a nationwide cohort study.","volume":"7","author":"Wester","year":"2023","journal-title":"Hepatol Commun"},{"issue":"36","key":"jrv260014r117","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.4254\/wjh.v9.i36.1332","article-title":"Hospital contacts with alcohol problems prior to liver cirrhosis or pancreatitis diagnosis.","volume":"9","author":"Askgaard","year":"2017","journal-title":"World J Hepatol"},{"issue":"2","key":"jrv260014r118","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2022.04.026","article-title":"The stigma of alcohol-related liver disease and its impact on healthcare.","volume":"77","author":"Schomerus","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"jrv260014r119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2025.08.002","article-title":"Alcohol use disorder: natural history, definitions, and stigma.","volume":"30","author":"Winder","year":"2026","journal-title":"Clin Liver Dis"},{"issue":"6","key":"jrv260014r120","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1097\/HEP.0000000000000989","article-title":"Alcohol-associated liver disease and public health policies.","volume":"80","author":"Sengupta","year":"2024","journal-title":"Hepatology"},{"issue":"10385","key":"jrv260014r121","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/S0140-6736(23)00497-X","article-title":"Evaluating the impact of alcohol minimum unit pricing on deaths and hospitalisations in Scotland: a controlled interrupted time series study.","volume":"401","author":"Wyper","year":"2023","journal-title":"Lancet"},{"key":"jrv260014r114","unstructured":"Chen? CMA, Hillel? R. Liver cirrhosis mortality in the United States: national, state, and regional trends, 2000-2023. National Institute on Alcohol Abuse and Alcoholism. September 2025. Accessed June 5, 2026. https:\/\/www.niaaa.nih.gov\/publications\/surveillance-reports\/surveillance123"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2851427\/jama_krag_2026_rv_260014_1784833424.42902.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:00:24Z","timestamp":1785855624000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2851427"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":121,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.12038","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}